9月11日，贵州三力大宗交易成交300万股，成交额3882万元，占当日总成交额的39.7%，成交价12.94 元，较市场收盘价12.94元持平。 | 交易日期 025-09-11 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 证券简称 费州三力 | | | | | | | | | | | 蓬券代码。 603439 | | | | | | | | | | | | 3882 | 300 | | | | | | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 12.94 | | | 海通证券股份有限 公司费阳长岭北路 | 美出营业部 海通证券股份有限 公司上海浦东分公 | 是否为专场 No | ...

Core Viewpoint - The A-share market shows a mixed performance with the Shanghai Composite Index at 3814.20 points, down by 1.14%, while the total trading volume reached 1.8782 trillion yuan, indicating a fluctuating market environment [1] Group 1: Market Performance - The Shanghai Composite Index is currently above the annual line, reflecting a slight decline of 1.14% [1] - The total trading volume of A-shares today is reported at 1.8782 trillion yuan [1] Group 2: Stocks Breaking Annual Line - A total of 12 A-shares have surpassed the annual line today, with notable stocks including: - Shangneng Electric (300827) with a deviation rate of 8.99% and a daily increase of 11.84% [1] - Renfu Pharmaceutical (600079) showing a deviation rate of 8.06% and a daily increase of 9.99% [1] - Saiteng Co., Ltd. (603283) with a deviation rate of 5.06% and a daily increase of 7.32% [1] - Other stocks with smaller deviation rates that have just crossed the annual line include: - ST Jinglun (600355) with a deviation rate of 0.53% and a daily increase of 1.14% [1] - Shichuang Energy (688429) with a deviation rate of 0.76% and a daily increase of 2.14% [1]

证券时报·数据宝统计，截至今日上午收盘，上证综指3820.98点，收于年线之上，涨跌幅为-0.96%，A 股总成交额为14721.76亿元。到目前为止，今日有10只A股价格突破了年线，其中乖离率较大的个股有 人福医药、上能电气、正帆科技等，乖离率分别为8.06%、7.79%、3.15%；金圆股份、蓝箭电子、四方 股份等个股乖离率较小，刚刚站上年线。 （文章来源：证券时报网） | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 600079 | 人福医 | 9.99 | 7.60 | 20.89 | 22.57 | 8.06 | | | 药 | | | | | | | 300827 | 上能电 | 10.60 | 17.55 | 25.74 | 27.75 | 7.79 | | | 气 | | | | | | | 688596 | 正帆科 | 4.01 | 3.71 | 35.49 | 36.61 | ...

Group 1 - The company Guizhou Sanli announced that it has not implemented share repurchase as of August 2025 [2] - As of August 31, 2025, the company has repurchased a total of 7,869,300 shares through centralized bidding, which accounts for 1.92% of the company's total share capital [2]

格隆汇9月1日丨贵州三力(603439.SH)公布，2025年08月01日至2025年08月31日期间，公司未实施回购 股份。截至2025年08月31日，公司通过集中竞价交易方式已累计回购股份7,869,300股，占公司截至本公 告日总股本的1.92%，回购最高价格为人民币14.20元/股，回购最低价格为人民币11.82元/股，支付的总 金额为99,954,426.00 ...

证券代码：603439 证券简称：贵州三力 公告编号：2025-051 贵州三力制药股份有限公司 关于股份回购进展公告 三、 其他事项 一、 回购股份的基本情况 贵州三力制药股份有限公司（以下简称"公司"）于 2024 年 9 月 12 日召开了第 四届董事会第四次会议，审议通过了《关于以集中竞价交易方式回购公司股份方 案的议案》。同意公司使用自有资金通过集中竞价交易方式进行股份回购，回购股 份将全部用于后期实施员工持股计划或股权激励计划，回购资金总额不低于人民 币 8,000.00 万元（含），不超过人民币 12,000.00 万元（含），回购价格不超过人民 币 17.85 元/股（含），回购期限自公司董事会审议通过回购股份方案之日起 12 个 月内。具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披露的《贵州 三力制药股份有限公司关于以集中竞价交易方式回购公司股份方案的公告暨回购 报告书》（公告编号：2024-054）。 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，每个月的前 3 个交易日内披露截至上月末 ...

Core Viewpoint - The increasing prevalence of throat diseases due to environmental pollution, lifestyle changes, and an aging population is driving the demand for throat traditional Chinese medicine (TCM), with the market expected to reach 7.4 billion yuan in 2024, reflecting a year-on-year growth of 7.49% [1][9]. Overview - Throat diseases are primarily caused by various factors such as wind-heat invasion and internal heat, leading to symptoms like sore throat and hoarseness. Throat TCM is made from traditional Chinese medicinal ingredients and is used to treat throat-related ailments, characterized by stable efficacy and minimal side effects [1][3]. Development History - The throat medicine industry in China began relatively late, with significant advancements in chronic pharyngitis research in the 1980s leading to the development of throat medications. The market was initially fragmented, but the introduction of products like Guangxi Jinsongzi's throat lozenges in 1995 marked a turning point, establishing a competitive landscape [4][5]. Market Policy - The Chinese government has implemented various policies to support the development of the TCM industry, creating a favorable environment for throat TCM growth. These include measures to enhance TCM regulation and promote innovation [5][6]. Industry Chain - The throat TCM industry consists of an upstream segment focused on medicinal herb cultivation, a midstream segment for manufacturing, and a downstream segment involving sales through medical institutions, pharmacies, and e-commerce platforms. The primary consumer groups include individuals who use their voices frequently and patients with chronic throat conditions [6][7][8]. Current Market Situation - The throat TCM market is experiencing rapid growth, with a projected sales figure of 7.4 billion yuan in 2024. Tablets represent the largest segment at 41.65%, followed by granules and pills [1][9]. Competitive Landscape - The throat TCM market is characterized by high concentration, with the top five companies holding over 50% market share in retail pharmacies. Guangxi Jinsongzi leads with a market share of 16.95% [10][11]. Key Companies - Guangxi Jinsongzi Group is a major player in the throat TCM market, with a projected revenue of 1.185 billion yuan in 2024 and a gross profit margin of 75.46% [12]. - Guilin Sanjin Pharmaceutical Co., Ltd. is another key player, with a projected revenue of 2.194 billion yuan in 2024 and a gross profit margin of 73.41% [12]. Future Trends - The throat TCM industry is expected to focus on improving the quality of raw materials and production processes to meet rising consumer demands for high-quality products. Additionally, there is potential for international market expansion, particularly in Southeast Asia, as awareness and acceptance of TCM grow [13].

证券之星价投圈财报分析工具显示：业务评价：公司去年的ROIC为13.01%，资本回报率强。去年的净 利率为13.05%，算上全部成本后，公司产品或服务的附加值高。从历史年报数据统计来看，公司上市 以来中位数ROIC为20.71%，投资回报也很好，其中最惨年份2020年的ROIC为9.89%，投资回报也较 好。公司历史上的财报相对良好(注：公司上市时间不满10年，上市时间越长财务均分参考意义越 大。)。商业模式：公司业绩主要依靠营销驱动。需要仔细研究这类驱动力背后的实际情况。 财报体检工具显示：建议关注公司现金流状况(货币资金/流动负债仅为36.96%)建议关注公司债务状况 (有息资产负债率已达26.43%)建议关注公司应收账款状况(应收账款/利润已达236.47%) | 基金筒称 | 基金代码 | 持有股数 | 持仓变动 | 数据来源 | | --- | --- | --- | --- | --- | | 鹏扬景沃六个月持有期混合A | 009064 | 21.00万股 新进十大 | | 2025基金半年报 | 据证券之星公开数据整理，近期贵州三力(603439)发布2025年中报。根据财报显示，贵州三力净利 ...

本报讯(记者冯雨瑶)8月27日晚间，贵州三力（603439）制药股份有限公司(以下简称"贵州三力")发布半 年报，报告期内实现营业收入7.02亿元，实现归属于上市公司股东的净利润0.83亿元。 上半年，公司紧密围绕既定发展战略和经营目标，重点开展了以下工作。一是持续推进营销体系战略性 重构，强化OTC渠道精细化运营，线上线下（300959）渠道协同发展。据了解，2024年公司已完成覆盖 全国的OTC直营网络布局，新设13家省级分公司，组建1700余人的专业化OTC营销团队，建立从"处方 渠道主导"向"OTC渠道为主、处方渠道协同"转型的战略目标。同时，公司成立电商中心，依托公司产 品积累的市场口碑，与京东健康、阿里健康等主流医药电商平台建立深度合作，同步推进电商渠道拓 展。 三是联合控股子公司云南无敌与贵阳工业发展基金等专业投资机构，于去年底设立黔力生物医药基金， 基金总规模5亿元，重点关注生物科技与健康管理赛道的股权投资项目。基金以"产业洞察+资本赋能"双 驱动模式，截至目前已储备十余个创新药标的。其中，多个产品进入Ⅲ期临床试验阶段。2025年上半 年，已完成个别项目投资交割，部分项目在尽调过程中。此举将逐 ...

（记者 王晓波） 每经AI快讯，贵州三力8月28日发布公告称，公司第四届第十五次董事会会议于2025年8月27日在公司 会议室以现场和通讯表决方式召开。会议审议了《公司2025年半年度报告及摘要》等文件。 每经头条（nbdtoutiao）——世界首例基因编辑猪肺成功移植人体 对话主要参与者：距离临床应用还有 多远？ ...